Table 2.

Font trial: Clinical outcomes

Participant	Up/c month 0	Up/c month 6	% Change Up/c	Up/c responder	eGFR month 0	eGFR month 6	eGFR preservation	Primary outcome met?	Duration (yr) follow-up post randomization
RX = Adalimumab
1	2.1	12.3	475.0	No	325	41	No	No	2.5
2	6.3	6.6	5.0	No	140	155	Yes	No	2.0
3	14.9	8.4	−43.8	No	88	116	Yes	No	1.6
4	4.7	6.1	31.0	No	120	93	Yes	No	1.7
5a,b	3.4	.	.	Never received study drug	81	.	Never received study drug	No	0.1
6	2.3	1.6	−30.5	No	37	29	Yes	No	1.5
7	2.1	5.2	142.5	No	58	24	No	No	1.7
RX = Galactose
8	9.0	3.2	−64.5	Yes	71	41	No	No	2.1
9	3.3	0.9	−72.8	Yes	143	129	Yes	Yes	1.7
10	3.3	0.5	−86.0	Yes	97	91	Yes	Yes	1.6
11	12.2	10.8	−11.4	No	91	63c	No	No	1.4
12a	49.3	29.9	−39.2	No	63	35	No	No	1.6
13	1.5	1.0	−29.9	No	221	180	Yes	No	1.3
14	6.7	7.0	4.7	No	71	67	Yes	No	1.1
RX = Standard Therapy (lisinopril, losartan, atorvastatin)
15	4.6	2.8	−40.3	No	276	283	Yes	No	2.1
16	16.0	5.0	−68.5	Yes	235	180	Yes	Yes	1.5
17a,b	11.6	.	.	Never received study drug	170	.	Never received study drug	No	0.0
18	3.2	2.5	−22.7	No	151	108	Yes	No	1.2
19	4.9	2.2	−54.6	Yes	155	150c	Yes	Yes	1.2
20	9.6	5.5	−42.2	No	173	178	Yes	No	1.7
21	11.5	14.2	23.2	No	94	.57c	No	No	1.8

Abbreviations: eGFR, estimated glomerular filtration rate; Up/C urine protein:creatinine ratio 1) Excludes the subject randomized to Rosiglitazone; 2) One participant in each arm was neither on ACEi, nor ARB ^a,Participant did not receive neither ACEi, nor ARB; ^b, Participant did not start assigned trial therapy; ^cParticipant had eGFR calculated based on testing performed at a local laboratory